Surrogate end points in heart failure trials.
Publication
, Journal Article
Gheorghiade, M; Adams, KF; Gattis, WA; Teerlink, JR; Orlandi, C; O'Connor, CM
Published in: Am Heart J
February 2003
Duke Scholars
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
February 2003
Volume
145
Issue
2 Suppl
Start / End Page
S67 / S70
Location
United States
Related Subject Headings
- Ventricular Remodeling
- Ventricular Function, Left
- Vasodilator Agents
- Treatment Outcome
- Stroke Volume
- Norepinephrine
- Neurotransmitter Agents
- Humans
- Heart Failure
- Exercise Tolerance
Citation
APA
Chicago
ICMJE
MLA
NLM
Gheorghiade, M., Adams, K. F., Gattis, W. A., Teerlink, J. R., Orlandi, C., & O’Connor, C. M. (2003). Surrogate end points in heart failure trials. Am Heart J, 145(2 Suppl), S67–S70. https://doi.org/10.1067/mhj.2003.159
Gheorghiade, Mihai, Kirkwood F. Adams, Wendy A. Gattis, John R. Teerlink, Cesare Orlandi, and Christopher M. O’Connor. “Surrogate end points in heart failure trials.” Am Heart J 145, no. 2 Suppl (February 2003): S67–70. https://doi.org/10.1067/mhj.2003.159.
Gheorghiade M, Adams KF, Gattis WA, Teerlink JR, Orlandi C, O’Connor CM. Surrogate end points in heart failure trials. Am Heart J. 2003 Feb;145(2 Suppl):S67–70.
Gheorghiade, Mihai, et al. “Surrogate end points in heart failure trials.” Am Heart J, vol. 145, no. 2 Suppl, Feb. 2003, pp. S67–70. Pubmed, doi:10.1067/mhj.2003.159.
Gheorghiade M, Adams KF, Gattis WA, Teerlink JR, Orlandi C, O’Connor CM. Surrogate end points in heart failure trials. Am Heart J. 2003 Feb;145(2 Suppl):S67–S70.
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
February 2003
Volume
145
Issue
2 Suppl
Start / End Page
S67 / S70
Location
United States
Related Subject Headings
- Ventricular Remodeling
- Ventricular Function, Left
- Vasodilator Agents
- Treatment Outcome
- Stroke Volume
- Norepinephrine
- Neurotransmitter Agents
- Humans
- Heart Failure
- Exercise Tolerance